BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31115144)

  • 1. A novel KMT2A-ACTN2 fusion in infant B-cell acute lymphoblastic leukemia.
    Yoshida M; Nakabayashi K; Ogata-Kawata H; Osumi T; Tsujimoto SI; Shirai R; Yoshida K; Okamura K; Matsumoto K; Kiyokawa N; Tomizawa D; Hata K; Kato M
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27821. PubMed ID: 31115144
    [No Abstract]   [Full Text] [Related]  

  • 2. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
    Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
    Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Gestrich CK; Sadri N; Sinno MG; Pateva I; Meyerson HJ
    Br J Haematol; 2020 Oct; 191(2):e61-e64. PubMed ID: 32729113
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants.
    Fazio G; Bardini M; De Lorenzo P; Grioni A; Quadri M; Pedace L; Corral Abascal L; Palamini S; Palmi C; Buldini B; Vinti L; Parasole R; Barisone E; Zecca M; Favre C; Locatelli F; Conter V; Rizzari C; Valsecchi MG; Biondi A; Cazzaniga G
    Blood; 2021 Apr; 137(14):1980-1984. PubMed ID: 33512459
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.
    Piciocchi A; Messina M; Elia L; Vitale A; Soddu S; Testi AM; Chiaretti S; Mancini M; Albano F; Spadano A; Krampera M; Bonifacio M; Cairoli R; Vetro C; Colella F; Ferrara F; Cimino G; Bassan R; Fazi P; Vignetti M
    Am J Hematol; 2021 Sep; 96(9):E334-E338. PubMed ID: 34048072
    [No Abstract]   [Full Text] [Related]  

  • 6. Inv(11)(q21q23); KMT2A-MAML2, a Recurrent Genetic Abnormality in T-Cell Therapy-related Acute Lymphoblastic Leukemia.
    Mariani RA; Silva M; Caparelli E; Jennings LJ; Yap KL; Leuer KM; Weinstein J; Gong S
    J Pediatr Hematol Oncol; 2020 May; 42(4):e258-e261. PubMed ID: 31343482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pediatric case of secondary T-cell acute lymphoblastic leukemia with KMT2A-MAML2 developing after hepatoblastoma treatment.
    Takahashi Y; Terui K; Chinen Y; Tandai S; Kudo K; Sasaki S; Tono C; Taki T; Ito E
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28033. PubMed ID: 31599492
    [No Abstract]   [Full Text] [Related]  

  • 8. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
    Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
    Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
    Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
    Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Ferrari A; Ghelli Luserna Di Rora A; Domizio C; Papayannidis C; Simonetti G; Maria Hernández-Rivas J; Rondoni M; Giglio F; Abruzzese E; Imovilli A; Iacobucci I; Calistri D; Martinelli G
    Br J Haematol; 2021 Mar; 192(6):e139-e144. PubMed ID: 33314053
    [No Abstract]   [Full Text] [Related]  

  • 11. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.
    Sanjuan-Pla A; Bueno C; Prieto C; Acha P; Stam RW; Marschalek R; Menéndez P
    Blood; 2015 Dec; 126(25):2676-85. PubMed ID: 26463423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel KMT2A-ARHGEF12 Fusion Gene Identified in a High-Grade B-cell Lymphoma.
    Jung HS; Lin F; Wolpaw A; Reilly AF; Margolskee E; Luo M; Wertheim GB; Li MM
    Cancer Genet; 2020 Aug; 246-247():41-43. PubMed ID: 32805689
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of KMT2A-MLLT3 fusion-positive mature B-cell acute lymphoblastic leukemia.
    Mitani Y; Arakawa Y; Mori M; Deguchi T; Koh K
    Pediatr Int; 2021 Jun; 63(6):719-722. PubMed ID: 33871895
    [No Abstract]   [Full Text] [Related]  

  • 14. DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites.
    Bergmann AK; Castellano G; Alten J; Ammerpohl O; Kolarova J; Nordlund J; Martin-Subero JI; Schrappe M; Siebert R
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27786413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings.
    Urtishak KA; Robinson BW; Rappaport EF; Sarezky MD; Biegel JA; Nichols KE; Wilmoth DM; Wang LS; Stern JW; Felix CA
    Pediatr Blood Cancer; 2016 Jul; 63(7):1175-80. PubMed ID: 26999444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
    Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
    Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
    Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
    Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of KMT2A-ARHGEF12 fusion in a child with a high-grade B-cell lymphoma.
    Schafernak KT; Williams JA; Clyde BI; Marcus C; Decker B; Toydemir RM
    Cancer Genet; 2021 Nov; 258-259():23-26. PubMed ID: 34237703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes.
    Ney Garcia DR; de Souza MT; de Figueiredo AF; Othman MAK; Rittscher K; Abdelhay E; Capela de Matos RR; Meyer C; Marschalek R; Land MGP; Liehr T; Ribeiro RC; Silva MLM
    Hematol Oncol; 2017 Dec; 35(4):760-768. PubMed ID: 27282883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.